Skip to main content
. 2019 Mar 22;17(5):4249–4258. doi: 10.3892/etm.2019.7427

Figure 5.

Figure 5.

Correlation analysis of TGF-β1, MCP-1 and IL-6 levels with (A and B) visual acuity improvement in patients treated with (A) aflibercept and (B) ranibizumab and with (C and D) central subfield thickness in patients treated with (C) aflibercept and (D) ranibizumab with an initial visual acuity letter score of ≥69. TGF, transforming growth factor; MCP, monocyte chemoattractant protein; IL, interleukin.